Full Text View
Tabular View
No Study Results Posted
Related Studies
Antipsychotic Response in Schizophrenia
This study has been completed.
First Received: July 3, 2001   Last Updated: January 20, 2009   History of Changes
Sponsored by: Department of Veterans Affairs
Information provided by: Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT00018668
  Purpose

Motor slowing is a hallmark, clinical sign in mental illness. Slowness can be related to a specific disease process, as in negative schizophrenia or depression or it can be the result of medications used to treat forms of mental illness. Prior research has lead to a novel instrumental approach for distinguishing subtypes of motor slowing - one type related to cognitive processes and another related to parkinsonism. The purpose of this study is to test whether new medications used to treat schizophrenia improve the cognitive or parkinsonian components of motor slowing. Patients will be studied in the laboratory before and 8-weeks after starting a new antipsychotic. The n of this study = 60 patients. The results of this study will improve our understanding of the complex interactions between cognitive processing and motor behavior in patients with psychotic illnesses and how drugs work to treat these problems.


Condition Intervention Phase
Schizophrenia
Drug: Risperidone
Drug: Olanzapine
Drug: Quetiapine
Phase IV

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title: Psychopharmacologic Aspects of Motor Slowing in Schizophrenia

Resource links provided by NLM:


Further study details as provided by Department of Veterans Affairs:

Study Start Date: October 2000
Estimated Study Completion Date: September 2004
  Eligibility

Ages Eligible for Study:   21 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Schizophrenia diagnosis currently treated with conventional antipsychotic willing to be switched to an atypical antipsychotic.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00018668

Locations
United States, California
Department of Veterans Affairs
San Diego, California, United States, 92161
Sponsors and Collaborators
  More Information

No publications provided

Study ID Numbers: MHBS-041-00S
Study First Received: July 3, 2001
Last Updated: January 20, 2009
ClinicalTrials.gov Identifier: NCT00018668     History of Changes
Health Authority: United States: Federal Government

Keywords provided by Department of Veterans Affairs:
Antipsychotics
schizophrenia
motor retardation
bradykinesia

Study placed in the following topic categories:
Neurotransmitter Agents
Tranquilizing Agents
Olanzapine
Risperidone
Psychotropic Drugs
Antiemetics
Central Nervous System Depressants
Antipsychotic Agents
Serotonin Uptake Inhibitors
Serotonin
Bradykinesia
Schizophrenia
Quetiapine
Dopamine
Mental Disorders
Dopamine Agents
Psychotic Disorders
Peripheral Nervous System Agents
Schizophrenia and Disorders with Psychotic Features

Additional relevant MeSH terms:
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Olanzapine
Psychotropic Drugs
Antiemetics
Schizophrenia
Serotonin Antagonists
Mental Disorders
Therapeutic Uses
Schizophrenia and Disorders with Psychotic Features
Tranquilizing Agents
Gastrointestinal Agents
Risperidone
Central Nervous System Depressants
Dopamine Antagonists
Antipsychotic Agents
Serotonin Uptake Inhibitors
Pharmacologic Actions
Quetiapine
Serotonin Agents
Autonomic Agents
Dopamine Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on September 04, 2009